by NeOnc Technologies | Jan 15, 2019
Main > NEO214 NEO214 Research | JAN. 15, 2019 NEO214 Shown To Be A Mediator Of Cell Death In Patients With TMZ-Resistant GBM Glioblastoma (GBM) is a highly aggressive primary brain tumor with a poor prognosis. Treatment with temozolomide, the current standard of...
by NeOnc Technologies | Jan 17, 2018
Main > NEO214 NEO214 Research | Jan. 17, 2018 NEO214 Effectively Kills Multiple Myeloma Cells With An Order Of Magnitude Stronger Than Its Individual Components Despite the introduction of new therapies for multiple myeloma (MM), many patients are still dying...
